Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors

1 Jan 2024

Abstract excerpt

ObjectiveThe open-label, phase II RATIONALE-209 study evaluated tislelizumab (anti-programmed cell death protein 1 antibody) as a tissue-agnostic monotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) tumors. MethodsAdults with previously treated, locally advanced unresectable or metastatic MSI-H/dMMR solid tumors were enrolled. Patients received tislelizumab 200 mg intravenously...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Genetic factors in colorectal cancer
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38988490
DOI: 10.21147/j.issn.1000-9604.2024.03.03

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumorsPMID 38988490Read ↗

Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trialSemantic proximity Read ↗

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 studySemantic proximity Read ↗

Real‐world data on microsatellite instability status in various unresectable or metastatic solid tumorsSemantic proximity Read ↗

Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 studySemantic proximity Read ↗

A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumoursSemantic proximity Read ↗

Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.Semantic proximity Read ↗

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.Semantic proximity Read ↗

Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical OutcomesSemantic proximity Read ↗

First Tissue-Agnostic Drug Approval IssuedSemantic proximity Read ↗

Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.Semantic proximity Read ↗

Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancerSemantic proximity Read ↗

Target-Driven Tissue-Agnostic Drug Approvals; a New Path of Drug DevelopmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.